ETR
Endogenous Tissue Restoration (ETR) is a new therapeutic approach, enabling the patient’s own body to naturally restore a new blood vessel or heart valve.
With ETR, the patient’s natural healing system develops tissue that pervades Xeltis’ device, forming a new, natural and fully functional blood vessel or heart valve within it. As ETR occurs, Xeltis implants are gradually absorbed by the body.
ETR is enabled by bioabsorbable polymers based on Nobel Prize awarded science.
Product Pipeline
Pre-Clinical
Clinical
Pediatric conduit
Pulmonary Heart Valve
Aortic Heart Valve
Cardiovascular Applications
Nobel Prize-Awarded Science
Jean-Marie Lehn, Nobel Laureate.
Awarded 1987 Nobel Prize in Chemistry for pioneering supramolecular chemistry, the science at the basis of Xeltis’ technology.
“Supramolecular chemistry enables Xeltis technology by providing unique biochemical and biomechanical properties, delivering solutions to issues faced by traditional materials over the course of decades.”
Professor Lehn is a Scientific Advisor to Xeltis.
Presented Data
2018
- EACTS 2018 Techno College
One-year case study on pediatric pulmonary valve - TCT 2018 annual meeting
Long-term aortic valve in vivo trial results - ECHSA 2018 annual meeting
Preliminary 1-year clinical results on pulmonary valve - ACC 2018 annual meeting
Heart valve preclinical and clinical trial program overview
2017
- TCT 2017 annual meeting
12-month preclinical data on aortic heart valve - EuroPCR 2017 annual meeting
6-month preclinical data on aortic heart valve. - 7th World Congress of Pediatric Cardiology & Cardiac Surgery (WCPCCS)
Xeltis 31-month feasibility clinical trial data of a novel bioabsorbable vascular graft in modified Fontan procedure
2016
- 30th European Association for Cardio-Thoracic Surgery (EACTS) annual meeting
Xeltis 2-year feasibility clinical trial data of a novel bioabsorbable vascular graft in modified Fontan procedure – mid-term results - 30th European Association for Cardio-Thoracic Surgery (EACTS) annual meeting
Xeltis 1-year in vivo data of a novel bioabsorbable pulmonary heart valved conduit - 96th American Association for Thoracic Surgery (AATS) annual meeting
Xeltis 1-year feasibility clinical trial data showed significant improvement in patients’ general conditions. - 3rd Heart Valve Society (HVS) annual meeting
Xeltis 1-year feasibility clinical trial data show significant improvement in patients’s general conditions. - 10th World Biomaterials Congress (WBC) annual meeting
Preclinical data on ETR validated potential of Xeltis technology to “guide the restoration of a patient’s natural tissue into a functional living vascular replacement.”